CAJ | 학술논문

目的:研究对下尿路症状(lower urinary tract symptom, LUTS)合并勃起功能障碍(erectile dysfunction, ED)的男性患者,α1受体阻滞剂和5-磷酸二酯酶抑制剂(Phosphodiesterase Type 5 inhibitor, PDE-5i)联合治疗相比于单药治疗的优势及安全性.方法:2012年1~5月我院门诊年龄>50岁、主诉LUTS合并ED的患者共35名.随机分为三组,坦索罗辛单药治疗组(n=12)、西地那非单药治疗组(n=11)、坦索罗辛和西地那非联合治疗组(n=12),共治疗12周.统计分析治疗前后国际前列腺症状评分(IPSS)和国际勃起功能评分(IIEF)有无改善.结果:坦索罗辛组、西地那非组、联合治疗组的IPSS和IIEF分别改善了50.3%和11.2%、10.1%和49.7%、61.2%和58.9%.三组治疗前后的IPSS和IIEF均有显著改善(P<0.05).其中,联合治疗组的IPSS和IIEF改善最明显.结论:对于LUTS合并ED的部分患者,α1受体阻滞剂和PDE-5抑制剂的联合治疗优于单药治疗.
목적:연구대하뇨로증상(lower urinary tract symptom, LUTS)합병발기공능장애(erectile dysfunction, ED)적남성환자,α1수체조체제화5-린산이지매억제제(Phosphodiesterase Type 5 inhibitor, PDE-5i)연합치료상비우단약치료적우세급안전성.방법:2012년1~5월아원문진년령>50세、주소LUTS합병ED적환자공35명.수궤분위삼조,탄색라신단약치료조(n=12)、서지나비단약치료조(n=11)、탄색라신화서지나비연합치료조(n=12),공치료12주.통계분석치료전후국제전렬선증상평분(IPSS)화국제발기공능평분(IIEF)유무개선.결과:탄색라신조、서지나비조、연합치료조적IPSS화IIEF분별개선료50.3%화11.2%、10.1%화49.7%、61.2%화58.9%.삼조치료전후적IPSS화IIEF균유현저개선(P<0.05).기중,연합치료조적IPSS화IIEF개선최명현.결론:대우LUTS합병ED적부분환자,α1수체조체제화PDE-5억제제적연합치료우우단약치료.
Objective:To investigate the advantages and safety of the combination of α1-receptor blocker and PDE-5i in treating LUTS and ED compared with monotherapy.Methods:Thirty-five cases aged 50 years or above who complained LUTS and ED were included. They were randomly divided into three groups: tamsulosin(n=12), sildenafil(n=11) and combination of both(n=12), and treated for 12 weeks. The IPSS and IIEF scores were analyzed.Results: Improvement of the IPSS and IIEF scores in all groups was significant(P<0.05).The improvement of the IPSS and IIEF scores in the combination group (61.2% and 58.9%, respectively) was greatest and there was significant difference compared with the tamsulosin group (50.3% and 11.2% respectively) or the sildenafil group (10.1% and 49.7% respectively). Conclusion:The combination of α1-receptor blocker and PDE-5i was superior to monotherapy in treating LUTS and ED.